High-risk localized and locally advanced prostate cancer patients treated with apalutamide – a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) – plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
To continue reading click here
